PIPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. PIPR is trading ~347 pre-market (below/near the key S1 support ~349.34) while momentum is still deteriorating (negative and expanding MACD histogram). With no Intellectia proprietary buy signals today (AI Stock Picker: none; SwingMax: none) and pattern-based odds skewing to further weakness over the next week/month, the risk/reward for an impatient entry is unfavorable ahead of earnings (2026-02-06 pre-market).
Trend/momentum: Bearish-to-weak. MACD histogram is -2.899 and negatively expanding, signaling downside momentum is strengthening. RSI(6) is 28.64 (near oversold), which can precede bounces, but oversold alone is not a buy trigger when MACD is still worsening. Levels: Pivot ~362.97 is well above price, reinforcing that the stock is trading below an important balance point. Immediate support is S1 ~349.34 (currently being tested/undercut in pre-market), then S2 ~340.92. Resistance levels sit at ~376.60 (R1) and ~385.02 (R2). Moving averages: Converging MAs suggests a transition phase, but current price action near/below support with negative MACD favors a bearish continuation unless price quickly reclaims S1 and then the pivot. Probabilistic trend (similar candlestick patterns): 80% chance of ~-1.25% over the next week and ~-6.55% over the next month, aligning with the current negative momentum backdrop.
citing best-in-class capital markets exposure and potential acceleration in mid-cap M&A; Wolfe reiterated Outperform and nudged PT higher (2026-01-07).
could re-rate shares if results/guidance beat expectations.
modestly supports franchise build-out.
with a negatively expanding MACD—this combination often precedes another leg down toward S2 (~340.
if support fails.
with a $385 PT, arguing Piper’s smaller-market-cap skew may limit upside EPS growth versus peers.
Latest quarter provided: 2025/Q3. Growth: Revenue $475.319M (+33.60% YoY), Net Income $60.266M (+73.23% YoY), EPS $3.38 (+72.45% YoY). This is strong operating leverage and earnings acceleration. Margins: Gross margin ~99.83% (slightly higher YoY), consistent with an advisory/capital-markets model. Takeaway: Fundamentals were strong in the latest reported quarter, but the stock’s current setup is being driven more by near-term technical/positioning and the upcoming earnings catalyst than by trailing-quarter strength alone. Politicians/congress: No recent congress trading data available; no politician/influential-figure activity provided. Hedge funds and insiders are reported as Neutral with no significant recent trends.
Recent trend: Mixed but leaning constructive overall. Upgrades/positives: Goldman upgraded to Buy (2025-11-09) with PT raised to $386; Wolfe maintained Outperform and nudged PT to $398 (2026-01-07). New negative coverage: BofA initiated Underperform (2026-01-26) with PT $385, highlighting potentially less upside versus peers due to deal-size exposure. Wall Street pros vs cons: Pros: Beneficiary of improving capital markets/M&A cycle; differentiated mid-cap M&A exposure; multiple bullish/Outperform-type stances with ~$386–$398 PTs. Cons: One notable Underperform initiation; upside may be capped versus peers if larger-deal activity drives the cycle; near-term technical weakness could overwhelm fundamentals until after earnings.
